Why has demand for platelet components increased? A review

Transfusion Medicine

Volumn 24, Issue 5, 2014, Pages 260-268

  Estcourt, L J ^a,b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

blood supply; platelets; transfusion

Indexed keywords

ACUTE MYELOID LEUKEMIA; AGING; BLOOD COMPONENT; CANCER PATIENT; HEART SURGERY; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; INAPPROPRIATE PRESCRIBING; INCIDENCE; INTENSIVE CARE; MYELODYSPLASTIC SYNDROME; PREVALENCE; REVIEW; SURVIVAL RATE; THROMBOCYTE DYSFUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 85007270643     PISSN: 09587578     EISSN: 13653148     Source Type: Journal    
DOI: 10.1111/tme.12155     Document Type: Review

References (80)

1. Allard, S., Grant-Casey, J., Murphy, G., Herbertson, M., Gill, R. & Murphy, M. (2013) National comparative audit of blood and component use in cardiac surgery. Transfusion Medicine, 23 (Suppl. 2), 39 (Abstract PO23).
2. Anderson, L., Quasim, I., Soutar, R., Steven, M., Macfie, A. & Korte, W. (2006) An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit. Transfusion Medicine, 16, 31–39.
3. Baldomero, H., Gratwohl, M., Gratwohl, A., Tichelli, A., Niederwieser, D., Madrigal, A., Frauendorfer, K. & European Group for Blood & Marrow Transplantation, EBMT (2011) The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplantation, 46, 485–501.
4. BCSH (2003) British Committee for Standards in Haematology: guidelines for the use of platelet transfusions. British Journal of Haematology, 122, 10–23.
5. Bilgin, Y.M., van de, Watering, L.M., Versteegh, M.I., van, Oers, M.H., Vamvakas, E.C. & Brand, A. (2011) Postoperative complications associated with transfusion of platelets and plasma in cardiac surgery. Transfusion, 51, 2603–2610.
6. Bolton-Maggs, P., Cohen, H. & on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group (2012) The 2011 Annual SHOT Report, SHOT. http://www.shotuk.org/shot-reports/ (Accessed 12/01/2014).
7. Bolton-Maggs, P., Poles, D., Watt, A., Thomas, D., Cohen, H. & on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group (2013) In: The 2012 Annual SHOT Report (ed Bolton-Maggs, P.), 200. Serious Hazards of Transfusion (SHOT), http://www.shotuk.org/shot-reports/ (Accessed 12/01/2014).
8. Burnett, A.K., Hills, R.K., Milligan, D. et al. (2011) Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 Trial. Journal of Clinical Oncology, 29, 369–377.
9. Butler, C., Doree, C., Estcourt, L.J., Trivella, M., Hopewell, S., Brunskill, S.J., Stanworth, S. & Murphy, M.F. (2013) Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database of Systematic Reviews (Online), 3, CD009072.
10. Cameron, B., Rock, G., Olberg, B. & Neurath, D. (2007) Evaluation of platelet transfusion triggers in a tertiary-care hospital. Transfusion, 47, 206–211.
11. Cancer Research UK. (2013) URL http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/ (Accessed 13/2/13).
12. CDC (2008) United States Cancer Statistics (USCS). National Program of Cancer Registries (NPCR). URL http://apps.nccd.cdc.gov/uscs/ (Accessed 7/2/13).
13. CDC. (2012) United States Cancer Statistics (USCS). National Program of Cancer Registries (NPCR). URL http://apps.nccd.cdc.gov/uscs/ (Accessed 7/2/13).
14. Charlton, A., Wallis, J., Robertson, J., Watson, D., Iqbal, A. & Tinegate, H. (2014) Where did platelets go in 2012? A survey of platelet transfusion practice in the north of England. Transfusion Medicine, 24, 213–218.
15. Chihara, D., Ito, H., Matsuda, T. et al. (2014) Differences in incidence and trends of haematological malignancies in Japan and the United States. British Journal of Haematology, 164, 536–545.
16. Coleman, M., Rachet, B., Woods, L. et al. (2004) Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. British Journal of Cancer, 90, 1367–1373.
17. Commonwealth of Australia. (2008) National Blood Authority Annual Report 2007–2008 http://www.blood.gov.au/nba-annual-report-2007-2008 (Accessed 14/01/2014).
18. Commonwealth of Australia. (2013) National Blood Authority Annual Report 2012–2013. http://www.blood.gov.au/pubs/1213report/pdf/NBA-AnnualReport-accessible-final.pdf (Accessed 14/01/2014).
19. De la Serna, J., Montesinos, P., Vellenga, E. et al. (2008) Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 111, 3395–3402.
20. Estcourt, L.J., Birchall, J., Lowe, D., Grant-Casey, J., Rowley, M. & Murphy, M.F. (2012) Platelet transfusions in haematology patients: are we using them appropriately? Vox Sanguinis, 103, 284–293.
21. Estcourt, L.J., Stanworth, S.J., Collett, D. & Murphy, M.F. (2014) Intracranial haemorrhage in thrombocytopenic haematology patients—a nested case–control study: the InCiTe study protocol. BMJ Open, 4, e004199.
22. Fernandez de Larrea, C., Jimenez, R., Rosinol, L. et al. (2014) Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. Bone Marrow Transplantation, 49, 223–227.
23. Fielding, A.K., Richards, S.M., Chopra, R. et al. (2007) Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood, 109, 944–950.
24. Garland, A., Olafson, K., Ramsey, C.D., Yogendran, M. & Fransoo, R. (2013) Epidemiology of critically ill patients in intensive care units: a population-based observational study. Critical Care Medicine, 17, R212.
25. Gratwohl, A., Baldomero, H., Passweg, J., Urbano-Ispizua, A. & Accreditation Committee of the European Group for Blood & Marrow Transplantation (2002) Increasing use of reduced intensity conditioning transplants: report of the 2001 EBMT activity survey. Bone Marrow Transplantation, 30, 813–831.
26. Gratwohl, A., Schmid, O., Baldomero, H., Horisberger, B., Urbano-Ispizua, A. & Accreditation Committee of the European Group for Blood & Marrow Transplantation (2004) Haematopoietic stem cell transplantation (HSCT) in Europe 2002. Changes in indication and impact of team density. A report of the EBMT activity survey. Bone Marrow Transplantation, 34, 855–875.
27. Gratwohl, A., Baldomero, H., Schmid, O., Horisberger, B., Bargetzi, M. & Urbano-Ispizua, A. (2005) Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplantation, 36, 575–590.
28. Gratwohl, A., Baldomero, H., Frauendorfer, K., Urbano-Ispizua, A. & Joint Accreditation Committee, I.S.f.C.T., European Group for Blood & Marrow Transplantation (2006) EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplantation, 37, 1069–1085.
29. Gratwohl, A., Baldomero, H., Frauendorfer, K., Rocha, V., Apperley, J., Niederwieser, D. & Joint Accreditation Committee of the International Society for Cellular, Therapy, European Group for Blood & Marrow Transplantation EBMT (2008) The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplantation, 41, 687–705.
30. Gratwohl, A., Baldomero, H., Schwendener, A. et al. (2009) The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies. Bone Marrow Transplantation, 43, 275–291.
31. Gratwohl, A., Baldomero, H., Schwendener, A., Gratwohl, M., Apperley, J., Frauendorfer, K. & Niederwieser, D. (2011) The EBMT activity survey 2008: impact of team size, team density and new trends. Bone Marrow Transplantation, 46, 174–191.
32. Greeno, E., McCullough, J. & Weisdorf, D. (2007) Platelet utilization and the transfusion trigger: a prospective analysis. Transfusion, 47, 201–205.
33. Heddle, N.M., Arnold, D.M., Boye, D., Webert, K.E., Resz, I. & Dumont, L.J. (2008) Comparing the efficacy and safety of apheresis and whole blood-derived platelet transfusions: a systematic review. Transfusion, 48, 1447–1458.
34. Heddle, N., Cook, R., Tinmouth, A. et al. (2009) A randomized controlled trial comparing standard and low dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood, 113, 1564–1573.
35. Henry, D.A., Carless, P.A., Moxey, A.J., O'Connell, D., Stokes, B.J., Fergusson, D.A. & Ker, K. (2011) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database of Systematic Reviews, 2011, CD001886.
36. Jones, A., Birchall, J., Roberts, P. et al. (2013) A survey of where and why platelets are used in hospitals in the South West region of England. Transfusion Medicine, 23, PO34.
37. Ma, X. (2012) Epidemiology of myelodysplastic syndromes. American Journal of Medicine, 125, S2–S5.
38. Ma, X., Does, M., Raza, A. & Mayne, S.T. (2007) Myelodysplastic syndromes: incidence and survival in the United States. Cancer, 109, 1536–1542.
39. MacLennan, S., Harding, K., Llewelyn, L., Choo, L., Bakrania, L., Massey, E. & Williamson, L. (2013) Comparison of platelets stored for 2-5 vs 6-7 days in preventing and treating haemorrhage in thrombocytopeinc patients - a randomised controlled trial. Vox Sanguinis, 105, 42.
40. Miller, Y., Bachowski, G., Benjamin, R. et al. (2007) Practice guidelines for blood transfusion. In: A Compilation from Recent Peer-Reviewed Literature. American National Red Cross.
41. Milligan, D.W., Wheatley, K., Littlewood, T., Craig, J.I.O., Burnett, A.K. & for the NCRI Haematological Oncology Clinical Studies Group (2006) Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood, 107, 4614–4622.
42. National Cancer Institute. (2013a) Surveillance, Epidemiology, and End Results Program (SEER) Stat Fact Sheets: Hodgkin Lymphoma. URL http://seer.cancer.gov/statfacts/ (Accessed 24/2/14).
43. National Cancer Institute. (2013b) Surveillance, Epidemiology, and End Results Program (SEER) Stat Fact Sheets: Leukemia. URL http://seer.cancer.gov/statfacts/ (Accessed 24/2/14).
44. National Cancer Institute. (2013c) Surveillance, Epidemiology, and End Results Program (SEER) Stat Fact Sheets: Myeloma. URL http://seer.cancer.gov/statfacts/ (Accessed 24/2/14).
45. National Cancer Institute. (2013d) Surveillance, Epidemiology, and End Results Program (SEER) Stat Fact Sheets: Non-Hodgkin Lymphoma. URL http://seer.cancer.gov/statfacts/ (Accessed 24/214).
46. Neukirchen, J., Schoonen, W.M., Strupp, C., Gattermann, N., Aul, C., Haas, R. & Germing, U. (2011) Incidence and prevalence of myelodysplastic syndromes: data from the Dusseldorf MDS-registry. Leukemia Research, 35, 1591–1596.
47. Office of National Statistics (ONS) (2012) Cancer incidence and mortality tables and charts tcm77-259491. Office of National Statistics. URL www.ons.gov.uk (Accessed 5/2/13).
48. Office of National Statistics (ONS). (2013a) Mid-year population estimates for the United Kingdom by country, annual mid-2001 to mid-2012. (ed. by figure1_tcm77-346352) Office of National Statistics. www.ons.gov.uk (Accessed 24/2/14).
49. Office of National Statistics (ONS). (2013b) Mid-1971 to Mid-2012 population estimates: quinary age groups for consituent countries in the United Kingdom; estimated resident population. (MYE6TS3C) Office of National Statistics. URL www.ons.gov.uk (Accessed 25/4/14).
50. Office of National Statistics (ONS). (2013c) 2012-based national population projections. Office of National Statistics. URL www.ons.gov.uk (Accessed 26/2/14).
51. Passweg, J.R., Baldomero, H., Gratwohl, A. et al. (2012) The EBMT activity survey: 1990-2010. Bone Marrow Transplantation, 47, 906–923.
52. Passweg, J.R., Baldomero, H., Bregni, M. et al. (2013) Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplantation, 48, 1161–1167.
53. Patel, B., Kirkland, K., Szydlo, R. et al. (2009) Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Haematologica, 94, 1399–1406.
54. Pendry, K. & Davies, T. (2011) An audit of the use and wastage in the North West of England and North Wales - where have all the platelets gone? Blood and Transfusion Matters, 34, 17–19.
55. Pietersz, R.N.I., Reesink, H.W., Panzer, S. et al. (2012) Prophylactic platelet transfusions. Vox Sanguinis, 103, 159–176.
56. van der Poel, C., Janssen, M. & Behr-Gross, M.-E. (2011a) Trends and Observations on the Collection, Testing and Use of Blood and Blood Components in Europe. 2001-2005 Report. Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM). http://www.edqm.eu/en/blood-transfusion-reports-70.html (Accessed 12/02/2014).
57. van der Poel, C., Janssen, M. & Behr-Gross, M.-E. (2011b) The Collection, Testing and Use of Blood Components in Europe 2006 Report. Directorate for the Quality of Medicines and HealthCare of the Council of Europe (EDQM). http://www.edqm.eu/en/blood-transfusion-reports-70.html (Accessed 12/02/2014).
58. van der Poel, C., Janssen, M. & Behr-Gross, M.-E. (2011c) The Collection, Testing and Use of Blood Components in Europe, 2007 Report. Directorate for the Quality of Medicines and Healthcare of the Council of Europe (EDQM). http://www.edqm.eu/en/blood-transfusion-reports-70.html (Accessed 12/02/2014).
59. van der Poel, C., Janssen, M. & Behr-Gross, M.-E. (2011d) The Collection, Testing and Use of Blood and Blood Components in Europe, 2008 Report. Directorate for the Quality of Medicines and Healthcare of the Council of Europe (EDQM). http://www.edqm.eu/en/blood-transfusion-reports-70.html (Accessed 12/02/2014).
60. Qureshi, H., Lowe, D., Dobson, P. et al. (2007) National comparative audit of the use of platelet transfusions in the UK. Transfusion Clinique et Biologique, 14, 509–513.
61. Rachet, B., Maringe, C., Nur, U. et al. (2009) Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. The Lancet Oncology, 10, 351–369.
62. Report of the US Department of Health and Human Services. (2011) The 2009 National Blood Collection and Utilization Survey Report. US Department of Health and Human Services, Office of the Assistant Secretary for Health, Washington, DC.
63. Rysler, C., Stoffel, N., Buser, A., Gratwohl, A., Tsakiris, D.A. & Stern, M. (2010) Effect of beta-blockers, Ca2 + antagonists, and benzodiazepines on bleeding incidence in patients with chemotherapy induced thrombocytopenia. Platelets, 21, 77–83.
64. Scottish Intensive Care Society Audit Group (SICSAG). (2013) Audit of critical care in Scotland 2013 reporting on 2012. http://www.sicsag.scot.nhs.uk/Publications/Main.htm (Accessed 14/04/2014).
65. Slichter, S.J., Kaufman, R.M., Assmann, S.F. et al. (2010) Dose of prophylactic platelet transfusions and prevention of hemorrhage. New England Journal of Medicine, 362, 600–613.
66. Snyder-Ramos, S.A., Mohnle, P., Weng, Y.S., Bottiger, B.W., Kulier, A., Levin, J. & Mangano, D.T. (2008) The ongoing variability in blood transfusion practices in cardiac surgery. Transfusion, 48, 1284–1299.
67. Spiess, B.D., Royston, D., Levy, J.H., Fitch, J., Dietrich, W., Body, S., Murkin, J. & Nadel, A. (2004) Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion, 44, 1143–1148.
68. Stanworth, S.J., Estcourt, L.J., Powter, G. et al. (2013a) A no-prophylaxis platelet transfusion strategy for hematologic cancers. New England Journal of Medicine, 368, 1771–1780.
69. Stanworth, S.J., Walsh, T.S., Prescott, R.J., Lee, R.J., Watson, D.M. & Wyncoll, D.L. (2013b) Thrombocytopenia and platelet transfusion in UK critical care: a multicenter observational study. Transfusion, 53, 1050–1058.
70. Stanworth, S.J., Estcourt, L.J., Llewelyn, C.A., Murphy, M.F., Wood, E.M. & for the TOPPS Study Investigators (2014) Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a sub-group analysis of a randomized trial. Transfusion, DOI:10.1111/trf.12646. [Epub ahead of print; 14/4/14].
71. Taylor, C., Cohen, H., Jones, H. et al. on behalf of the SHOT Steering Group (2008) Annual Report 2007 Serious Hazards of Transfusion (SHOT). http://www.shotuk.org/shot-reports/ (Accessed 12/01/2014).
72. Taylor, C.E., Cohen, H., Mold, D. et al; on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group (2009) The 2008 Annual SHOT Report.
73. The Health and Social Care Information Centre. (2013) Adult critical care in England April 2011 to March 2012. URL www.ic.nhs.uk (Accessed 27/2/14).
74. Tinegate, H., Chattree, S., Iqbal, A., Plews, D., Whitehead, J., Wallis, J.P. & Northern Regional Transfusion Committee (2013) Ten-year pattern of red blood cell use in the North of England. Transfusion, 53, 483–489.
75. Wandt, H., Schaefer-Eckart, K., Wendelin, K. et al. (2012) Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet, 380, 1309–1316.
76. Wardrop, D., Estcourt, L., Brunskill, S.J., Doree, C., Trivella, M., Stanworth, S. & Murphy, M. (2013) Antifibrinolytics (lysine analogues) for the prevention of bleeding in patients with haematological disorders. Cochrane Database of Systematic Reviews (Online), CD009733.
77. Wells, A.W., Llewelyn, C.A., Casbard, A. et al. (2009) The EASTR study: a new approach to determine the reasons for transfusion in epidemiological studies. Transfusion Medicine, 19, 315–328.
78. Whitaker, B.I. & Hinkins, S. (2013) The 2011 National Blood Collection and Utilization Survey Report. US Department of Health and Human Services, Rockville, MD.
79. Whitaker, B.I. & Sullivan, M. (2007) The 2005 Nationwide Blood Collection and Utilization Survey. US Department of Health & Human Services, Washington DC.
80. Whitaker, B.I., Green, W.-J., King, M.R., Leibeg, L.L., Mathew, S.M., Schlumpf, K.S. & Schreiber, G.B. (2008) The 2007 National Blood Collection and Utilization Report. US Department of Health & Human Services. DHHS, Washington DC.